Capital eventCH· 3mo ago
EQS-News: Pentixapharm beschliesst Bezugsrechtskapitalerhöhung zur Finanzierung der PANDA Phase-3-Studie und der US-Expansion | 01.07.26 | finanzen.ch
Pentixapharm plans a rights issue to fund the PANDA Phase-3 study and US expansion.
Intent
WATCH· 54intent / 100
▸ why this score▾ score breakdown
- default: OON discount · × 0.75-0.3
- Final score (ambiguity-dampened) · default=54+54
- V2 winner: default · default=54+0
Go-to-market brief
EQS-News
companyCH
Daily 5 RWA signals
Five signals in your inbox each morning. Email only.
Free. The daily 5 lands at 07:00 UTC, nothing else. One-click unsubscribe in every email.